Request Free Sample
×
GCC Ascites Market
ID: MRFR/HC/54591-HCR
200 Pages
February 2026
GCC Ascites Market Research Report: By Type (Transudative Ascites, Exudate Ascites), By Diagnosis (Ultrasound, CT Scan, Laparoscopy, Angiography), By Treatment (Surgeries) andBy End User (Hospitals & Clinics, Ambulatory Surgical Center, Diagnostic Centers)- Forecast to 2035
Industry Developments
Recent developments in the GCC Ascites Market highlight a growing focus on innovative treatment options and regulatory changes. In September 2023, Pfizer announced enhancements in its pipeline targeting ascites-related conditions, showcasing its commitment to addressing patient needs. Similarly, Gilead Sciences has been actively collaborating with healthcare providers to optimize treatment protocols within the region, reflecting the rising demand for improved patient outcomes. Meanwhile, AbbVie emphasized its research initiatives aimed at expanding therapeutic options for ascites patients in the GCC, aligning with the region’s healthcare advancement goals. Notably, in August 2023, Merck and Co completed strategic collaborations with local healthcare entities in the GCC to introduce their latest ascites management therapies. In terms of market valuation, companies like Bristol Myers Squibb and Amgen have reported substantial growth, fueling investments in research and clinical trials pertinent to ascites management. Over the past two years, the GCC market has experienced notable transformations, particularly through regulatory updates in healthcare policies and an increased focus on patient-centered care strategies, which encompass advancements in diagnostic and therapeutic technologies addressed by companies like Stryker Corporation and Fresenius Kabi.
Report Scope
Report Scope:
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 77.4(USD Million) |
| MARKET SIZE 2024 | 81.6(USD Million) |
| MARKET SIZE 2035 | 162.2(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.445% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Pfizer, Eli Lilly and Company, AbbVie, Gilead Sciences, Fresenius Kabi, BristolMyers Squibb, Amgen, Terumo Corporation, Acelity, Sanofi, Stryker Corporation, Baxter International, Becton Dickinson, Janssen Pharmaceuticals, Merck & Co |
| SEGMENTS COVERED | Type, Diagnosis, Treatment, End User |
| KEY MARKET OPPORTUNITIES | Increasing prevalence of liver diseases, Advancements in diagnostic technologies, Growing demand for targeted therapies, Rising healthcare expenditure, Emerging markets and patient awareness |
| KEY MARKET DYNAMICS | increasing prevalence of liver diseases, rising geriatric population, growing healthcare expenditure, advancements in treatment options, awareness and education initiatives |
| COUNTRIES COVERED | GCC |
Leave a Comment
FAQs
What is the expected market size of the GCC Ascites Market in 2024?
The GCC Ascites Market is projected to be valued at 81.6 million USD in 2024.
What will be the estimated value of the GCC Ascites Market by 2035?
The market is expected to reach a value of 162.2 million USD by the year 2035.
What is the compound annual growth rate (CAGR) for the GCC Ascites Market from 2025 to 2035?
The expected CAGR for the GCC Ascites Market during this period is 6.445 percent.
Which type of ascites is expected to dominate the market by 2035?
Transudative Ascites is expected to dominate the market, valued at 98.0 million USD in 2035.
What is the market size of Exudate Ascites in 2024?
Exudate Ascites is projected to be valued at 32.6 million USD in 2024.
Who are the major players in the GCC Ascites Market?
Key players include Pfizer, Eli Lilly and Company, AbbVie, and Gilead Sciences among others.
What are the primary growth drivers for the GCC Ascites Market?
Increasing prevalence of liver diseases and advancements in treatment options are the primary growth drivers.
How is the GCC Ascites Market expected to fare regionally?
The market is anticipated to show robust growth across the Gulf Cooperation Council region.
What is the projected market size for Transudative Ascites in 2024?
Transudative Ascites is expected to be valued at 49.0 million USD in the year 2024.
What challenges may impact the GCC Ascites Market in the coming years?
Challenges may include high treatment costs and limited access to advanced therapies in certain regions.
Download Free Sample
Kindly complete the form below to receive a free sample of this Report
Customer Stories
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
Noah Malgeri
Co-Founder
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
Joseph Aguayo
Sales Operations & Pricing Manager
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
Peter Groot koerkamp
Account and Business Manager
“Thank you, this will be very helpful for OQS.”
La Terria Dodd
Program Support Specialist
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
Younghwan Choi
Senior Retail Manager
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
Mark Irwin
Management Consultant
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”
Akif Moroglu
Strategy & Business Development Director
Case Study
Aerospace & Defense